|
Argenx - Reaching Patients Through Immunology Innovation
At argenx, we’ve created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways and differentiated therapeutic antibodies.
Investors - Argenx
At argenx, our commitment to ESG is about measuring our progress as a business based on core components that will sustain us on our path to be an integrated, immunology company.
Argenx - Wikipedia
Argenx SE (Euronext Brussels: ARGX ) is a Belgian - Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs.
argenx SE (ARGX) Stock Price, News, Quote & History - Yahoo Finance
Find the latest argenx SE (ARGX) stock quote, history, news and other vital information to help you with your stock trading and investing.
argenx Careers
At argenx, we are redefining how a biotech company can advance science and deliver innovative treatments. We're enabling new ways of working with partners, patients and each other. We develop our business by developing our people.
Argenx acquires Forte for $2.2B for ph.2-stage vitiligo drug
Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.
argenx - LinkedIn
United in our commitment to improve the lives of patients | argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases.
Our products - argenx
MyPATH, argenx's Patient Support Program is committed to supporting people throughout their treatment journey. At the MyPATH Patient Support Program, we understand that living with a chronic condition like generalized Myasthenia Gravis (gMG) is different for everyone.
Forte Biosciences Inc - argenx to Acquire Forte Biosciences, Inc ...
Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases with high unmet need that have lacked innovation Acquisition strengthens argenx’s ...
argenx SE (ARGX) Stock Price & Overview
A detailed overview of argenx SE (ARGX) stock, including real-time price, chart, key statistics, news, and more.
|
FIRE101 Fire Jobs 